MAA (Molecular Affinity Analysis) is a platform for in situ detection and quantification of therapeutic binding sites on patient tumor tissue. It enables precise assessment of target accessibility, binding site density, and spatial distribution, providing critical insights for biomarker validation, patient stratification, and therapy optimization. MAA is compatible with a wide range of therapeutics, including small molecules, monoclonal antibodies, bispecific antibodies, ADCs, radioligands, and CAR-T cell targets, making it a versatile approach for advancing precision oncology.
MAA integrates seamlessly into various workflows, from preclinical drug development to exploratory clinical research, supporting applications such as drug-target interaction mapping, patient stratification, and therapy exploration for challenging cases. It serves researchers, clinical trial investigators, and drug developers alike, across all stages of the scientific and clinical development pathway. The platform supports precision in oncology research by delivering molecular insights relevant to the drug development pipeline
The MAA (Molecular Affinity Analysis) platform can be adapted to your individual requirements, to detect the therapeutic binding sites of your drug or target of interest. Whether you are a pharmaceutical or biotech company or a research group, MAA supports you throughout the drug development process, from preclinical research to clinical trials.
Adaptation takes place in close collaboration with you, with end-to-end support and efficient timelines. This enables you to quantify drug-target interactions in situ, supporting the optimization of your molecular designs, patient selection, and trial outcomes.
The Clinical Trial Stratification Service, based on the MAA (Molecular Affinity Analysis) platform, supports patient stratification in clinical trials by detecting therapeutically relevant regions in tumor tissue and assessing the accessibility and density of therapeutic binding sites.
This service supports clinical trial design by identifying patients with tumor profiles relevant to the therapy, enabling the exploration of predictive biomarkers and supporting the enrichment of trial populations for therapies like ADCs, monoclonal antibodies, bispecific antibodies, radioligands and small molecules.
Our MAA-based Drug Repurposing and Cross-Tumor Affinity Screening Service, evaluates the binding affinity of investigational or approved drugs across diverse tumor types.
By identifying potential new therapeutic opportunities or assessing off-target binding, this service supports researchers and drug developers in exploring repurposing strategies, informing trial risk assessment, and broadening the therapeutic scope of existing assets.
The Patient-Specific Drug Affinity Profiling Service uses MAA (Molecular Affinity Analysis) to test drug binding to therapeutically relevant regions in patient-derived tumor tissue, providing molecular insights into potential treatment options for challenging oncology cases.
While designed for research purposes, this service supports oncologists in exploring personalized therapy pathways and precision oncology approaches for patients with limited treatment options.
We invite you to connect with us to explore how our Molecular Affinity Analysis (MAA) platform can address your research and clinical objectives. Whether your focus is on enhancing clinical trial strategies, or advancing therapeutic profiling, our team is ready to provide tailored support and expert guidance.
Contact us to discuss your specific needs, request detailed information, or learn more about how MAA technology can contribute to your success in drug development and precision oncology.
